Please use this identifier to cite or link to this item: https://doi.org/10.1097/JTO.0b013e31826baf83
DC FieldValue
dc.titleTargeting ROS1 with anaplastic lymphoma kinase inhibitors: A promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer
dc.contributor.authorChin, L.P.
dc.contributor.authorSoo, R.A.
dc.contributor.authorSoong, R.
dc.contributor.authorOu, S.-H.I.
dc.date.accessioned2014-12-12T07:16:56Z
dc.date.available2014-12-12T07:16:56Z
dc.date.issued2012-11
dc.identifier.citationChin, L.P., Soo, R.A., Soong, R., Ou, S.-H.I. (2012-11). Targeting ROS1 with anaplastic lymphoma kinase inhibitors: A promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer. Journal of Thoracic Oncology 7 (11) : 1625-1630. ScholarBank@NUS Repository. https://doi.org/10.1097/JTO.0b013e31826baf83
dc.identifier.issn15560864
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/115550
dc.description.abstractChromosomal rearrangements involving the ROS1 receptor tyrosine kinase have been described in a variety of human malignancies including non-small-cell lung cancer (NSCLC), cholangiocarcinoma and glioblastoma multiforme. Recently, clinicopathologic characteristics of c-ros oncogene 1, receptor tyrosine kinase (ROS1)-rearranged NSCLC patients have been described. Furthermore, anaplastic lymphoma kinase inhibitor, novel class of drugs targeting this tyrosine kinase receptor is currently under clinical trial in this molecular subset of NSCLC patients. This review will focus on the current knowledge of ROS1 rearrangements in NSCLC, methods to detect ROS1 rearrangement, and targeting ROS1-rearranged NSCLC patients with anaplastic lymphoma kinase inhibitors. Copyright © 2012 by the International Association for the Study of Lung Cancer.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1097/JTO.0b013e31826baf83
dc.sourceScopus
dc.subjectAnaplastic lymphoma kinase inhibitors
dc.subjectCrizotinib
dc.subjectNon-small-cell lung cancer
dc.subjectROS1
dc.subjectTargeted therapy
dc.typeReview
dc.contributor.departmentCANCER SCIENCE INSTITUTE OF SINGAPORE
dc.description.doi10.1097/JTO.0b013e31826baf83
dc.description.sourcetitleJournal of Thoracic Oncology
dc.description.volume7
dc.description.issue11
dc.description.page1625-1630
dc.identifier.isiut000310057000008
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

111
checked on Dec 8, 2022

WEB OF SCIENCETM
Citations

97
checked on Dec 8, 2022

Page view(s)

260
checked on Dec 8, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.